| 產(chǎn)品名稱 | ICA-069673 |
| 產(chǎn)品貨號 | Axon 2724 CAS [582323-16-8] MF C11H6ClF2N3OMW 269.63 Purity: 99% Soluble in DMSO Description ICA-069673, a Kv7.2/Kv7.3 (KCNQ2/Q3) channel opener (EC50 value 0.69 μM), demonstrated 20-fold greater selectivity for heteromeric Kv7.2/Kv7.3 channels over Kv7.3/Kv7.5. Moreover, compared to retigabine (Axon 1525), ICA-069673 exhibits much stronger effects on KCNQ2 channels, including a large hyperpolarizing shift of the voltage-dependence of activation, an ~2-fold enhancement of peak current and pronounced subtype specificity for KCNQ2 over KCNQ3. Orally active in several animal models of epilepsy. KEYWORDS: ICA-069673 | supplier | KCNQ channel opener | ICA069673 | ICA 069673 | CAS [582323-16-8] | Potassium | Kv7.2 | Kv7.3 | Opener | Ion Channels | KCNQ2 | KCNQ3 | Anti-convulsant | KCNQ2/Q3 |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
ICA-069673Axon 2724 CAS [582323-16-8] MF C11H6ClF2N3O
DescriptionICA-069673, a Kv7.2/Kv7.3 (KCNQ2/Q3) channel opener (EC50 value 0.69 μM), demonstrated 20-fold greater selectivity for heteromeric Kv7.2/Kv7.3 channels over Kv7.3/Kv7.5. Moreover, compared to retigabine (Axon 1525), ICA-069673 exhibits much stronger effects on KCNQ2 channels, including a large hyperpolarizing shift of the voltage-dependence of activation, an ~2-fold enhancement of peak current and pronounced subtype specificity for KCNQ2 over KCNQ3. Orally active in several animal models of epilepsy. KEYWORDS: ICA-069673 | supplier | KCNQ channel opener | ICA069673 | ICA 069673 | CAS [582323-16-8] | Potassium | Kv7.2 | Kv7.3 | Opener | Ion Channels | KCNQ2 | KCNQ3 | Anti-convulsant | KCNQ2/Q3
KCNQ2/KCNQ3 channel opener; Anti-convulsant
Chemical nameN-(2-Chloropyrimidin-5-yl)-3,4-difluorobenzamide Parent CAS No.[582323-16-8] |
| 產(chǎn)品資料 |
